Idogen Running Out Of Survival Options
Swedish Firm Seeking Reverse Merger Solution
With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.
You may also be interested in...
The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.